Veronica Gambillara Fonck

As Chief Executive Officer of GlycoEra, Veronica brings an innovative and complementary approach to corporate and product strategy development, thanks to her differentiated and multidisciplinary working experience.

From 2015 to 2020, Veronica was leading LimmaTech as CEO and member of the Board of Directors. LimmaTech is a spin-off of GlycoVaxyn, the company acquired by GlaxoSmithKline plc in February 2015. Veronica joined GlycoVaxyn in 2009, and during the 6 years at the firm, she held different positions, from leading the clinical and regulatory department to taking care of the business development of the company. Before joining GlycoVaxyn, she held leading roles in medical technology and biotechnology companies, including EndoArt SA and Allergan Inc, focused on clinical R&D and international regulatory affairs. Veronica holds an engineering degree from the Swiss Federal Institute of Technology, Zurich (ETH Zurich) and a PhD in life sciences in the field of cardiovascular biomedical engineering from the Swiss Federal Institute of Technology, Lausanne (EPFL). She is the author of several articles in research and clinical development.